How Can Art Therapy Benefit Those With AD and Other Forms of Dementia?


Aging can be hard to embrace, but it can also be a time to try new things and explore interests that time may not have allowed in the past. Working with an art therapist to process past and current life events and the challenges of aging offers a space to improve overall quality of life. Art therapy helps exercise the brain, increasing one’s quality of life through sensory stimulation and self-expression.

What exactly is art therapy?

Art Therapy, facilitated by a professional art therapist, effectively supports personal and relational treatment goals as well as community concerns. Art Therapy is used to improve cognitive and sensory-motor functions, foster self-esteem and self-awareness, cultivate emotional resilience, promote insight, enhance social skills, reduce and resolve conflicts and distress, and advance societal and ecological change. (1)

Art therapy with individuals with various forms of dementia may be underutilized because the idea of making “art” can be very intimidating. For some, cognitive deficits may hinder their ability to process or discuss their experiences. When making art, we are used to focusing on the aesthetic outcome of the art piece and it can be difficult to consider oneself an “artist.” Many older adults have little to no experience using art materials and may not know how they might visually express themselves. If this pressure to create a beautiful piece of fine art is taken away and the focus shifts to the process rather than the product, the activity becomes more enjoyable. It can also be beneficial to do art therapy in group settings to encourage social interaction between the group members. 

Clinical art therapy with older adults experiencing Alzheimer’s disease (AD) and other dementias is primarily focused on three areas; working with the person’s immediate problem, navigating issues related to aging, and providing the client with a sense of self worth. Focusing on past and current strengths is helpful, as well as, engaging in artwork that helps increase social interaction and maintenance of cognitive skills. In this setting the art therapist takes on a supportive role, as opposed to a more insight-oriented role due to the cognitive decline those in various stages of AD may be experiencing. 

Throughout the disease, cognitive decline gradually increases and hinders communication abilities in those with AD, leaving them with fewer ways to express themselves. In later stages of the disease passive behaviors such as apathy, lack of environmental interaction, and decrease in gross motor movement become more present. Art therapy can help these individuals develop an alternative way of expressing themselves and continue to battle their disease with grace and encourage a higher quality of life.

Aspects of cognitive decline are visible in the client’s artwork and can provide insight on which areas of the brain may be more affected by AD. Some researchers maintain that the progression of decline can be tracked by the client’s artwork as well. Studies have found that there are graphic indicators of AD that can be found within the artwork, such as fragmentation, disorganization, simplification, regression, perseveration, distortions, overlapping configurations, confused perspective, perceptual rotation, small or cramped appearance, use of short scattered lines, omitted essential details from a drawing, and difficulty following directions. By tracking these indicators across sessions, clinicians may be better informed when planning treatment strategies to slow disease progression.

It is important to remember that each individual experiencing AD or other forms of dementia have a different experience and have strengths unique to that individual. Art therapy interventions can help to provide alternate ways for the elderly to communicate and express themselves. More research into the integration of art therapy and neuroscience is needed to fully understand the benefits and limitations of this method of treatment. Some long-term and assisted living care facilities have already begun offering art therapy resources to their residents, but many others are limited in the programs they can offer this demographic. Perhaps art therapy methods can one day be seen as a cost effective addition to treatment and work along side of the prescribed medications that help to slow cognitive decline and the progression of AD and other dementias.

(1) About Art Therapy. (n.d.). Retrieved October 30, 2019, from 
(2) Stewart, E. G. (2004). Art Therapy and Neuroscience Blend: Working with Patients Who Have Dementia. Art Therapy, 21(3), 148–155. doi: 10.1080/07421656.2004.10129499

The Alzheimer Epidemic: Urgent Treatment Needed Now

It is normal for our brains to shrink as we age but abnormal to lose basic cognitive function or brain cells in large numbers.  Alzheimer’s disease kills our brain cells, known as neurons, leading to thinking and memory decline. Overtime, affected individuals will gradually lose their ability to live independently. Over 5 million Americans have Alzheimer’s disease, 65,000 of those individuals reside in Oregon with another 110,000 in Washington. Between 2017 and 2018 there was a $20 billion rise in total care spent for individuals suffering from Alzheimer’s disease. It is becoming increasingly clear that better treatments are needed now more than ever.

Naturally occurring amyloid protein collect between neurons to form plaques.  Abnormally folded tau protein forms neurofibrillary tangles inside neurons blocking their transport system and preventing communication with other neurons. When neurons are damaged connections between neural networks degrade causing brain regions to shrink, or atrophy (see Figure 1 showing brain shrinkage over a one year period in a patient with early disease). The brain areas most affected are responsible for memory, as the disease progresses it continues to affect other regions essential for language, reasoning, and more.

Figure 1. MRI scans of patient with MCI at baseline and 1 year later in follow-up; arrows point to the memory circuit called the hippocampus which has rapidly atrophied.

The disease can be divided into three stages. The first stage is called preclinical Alzheimer’s disease where subtle cognitive changes occur and often go unnoticed. The second stage–prodromal Alzheimer’s disease–or mild cognitive impairment (MCI), is when memory problems become obvious to family members, but the affected person can still live alone. The last stage is called Alzheimer’s disease dementia, where the individual’s ability to perform independent activities of daily living is impaired.

An Alzheimer’s diagnosis is confirmed by clinical interpretation and biomarker identification by measuring amyloid in the cerebral spinal fluid or with Amyloid-PET (Positron Emission Tomography) scans. These scans make it possible for us to view the amyloid plaques and, with Tau-PET, the tangles within the brain; allowing us to identify individuals at risk for the disease even before symptoms arise. Unfortunately, these PET scans are very expensive, slightly invasive, and often times not covered by insurance, including Medicare. Establishing a blood test to detect at risk individuals is urgent. Numerous research groups have been working towards this goal with one test, by the company Shimadzu Corp, being 88% accurate at identifying those at risk. Early detection of the disease is necessary as we have learned that anti-amyloid drugs do not work in individuals with prodromal or full-blown Alzheimer’s disease.

There are few treatment options currently available, drugs like Aricept and Namenda, only successfully treat symptoms in a minority of patients. There is no cure for Alzheimer’s disease. The need for a disease modifying agent to combat Alzheimer’s disease is growing. New drugs are being tested to halt the progression or prevent the initiation of the disease. The most common targets for these drugs are amyloid protein, tau protein, and the brain inflammation these mis-folded proteins cause.

A change has recently occurred within Alzheimer’s disease research. The lack of efficacy of anti-amyloid drugs in people with symptoms has motivated researchers to target factors other than amyloid, such as the mis-folded tau protein, and brain inflammation. Our fight against Alzheimer’s disease continues at the Center for Cognitive Health as we continue to work within the global research community seeking the first ever FDA-approved disease modifying medication for Alzheimer’s disease. 


The Village Landais Alzheimer – France’s New Care Facility

A 17-acre elderly care village named Landais Alzheimer is currently being built near the city of Dax nestled in southwestern France. It may appear to be a senior living community like any other, but it’s unique in that it’s a village developed entirely for men and women suffering from Alzheimer’s disease (AD).

Henri Emmanuelli developed the idea after reading about a similarly established care facility for individuals with dementia in the Netherlands. Largely governmentally funded, the Village Landais Alzheimer is anticipated to cost around $36 million dollars once completed, with an expected daily resident cost of only $82 per day, which is comparable to the daily rate for traditional French nursing homes. Now-a-days, with increasing costs of care as we age, not everyone can attend a private care facility or maintain the ability to stay home despite help. The Village Landais Alzheimer is Henri’s solution.

The Village

The community is equipped with a salon, gym, restaurant, garden, 5-acre park, library, and even a small farm! Residents will maintain a sense of independence and normality by shopping in a small supermarket for their individual needs, and most importantly, in a safe space developed especially for them. The architecture will allow for residents to walk, navigate, and orient themselves within the community, something that can often prove challenging for individuals with AD.

The houses are arranged in four square-like districts that surround a central commons ground offering most amenities and an auditorium. Residents will share housing designed to respect various lifestyles and their independence and privacy, offering a familiar family way of life. Sixteen houses with 7-8 residents will reside in one of four neighborhoods. All attempts were made to make the village feel as if it’s a regular, every-day village. The neighborhoods are named after nearby towns found between Frances southwestern sea and forest, and are designed with styles to match. To help patients feel appropriately oriented the village used a more traditional and familiar look of a medieval fortified town, common in this region of France, rather than modern architecture.

Medical staff without any visible identifiers and in plain clothing will watch over residents as they go about their daily lives and may provide care if needed. Trained volunteers will be present for daily activities that sometimes consist of outside events, like sports games and plays. These volunteers, mostly from the surrounding community, will breathe life into the village and provide a link between the village and the ‘outside world’. The facility will not be an isolated village, but rather open to the town of Dax, which will help to introduce further culture. Trained dogs will also be available to prevent the psychosocial isolation often accompanied with aging and AD. 

Why create an entire community dedicated to people with AD?

It will allow individuals with AD to increase their freedom while also reducing anxiety, which is a side effect highly associated with AD. The facility is hoped to create a sense of normality, community, and continuity between pre and post AD diagnosis, with an emphasis on maintaining socialization. Advocates for the village expect residents to be happier with increased activity and less required medication when compared to traditional living facilities. The fact that a place exists specifically catered to caring for loved one’s with AD, without sacrificing quality of life, should also help to lessen the worry of friends and family.

Unlike the already established Dutch site in the Netherlands, 120 young researchers will cohabitate with the Alzheimer’s residents along with 100 live-in caretakers and 120 volunteers. The researchers will identify the impact of their residential approach on patients, caregivers, and medical staff with a comparative study with traditional nursing homes. The facility is expected to open at the end of 2019. Depending on the results of the associated research, it may change the way we currently view residential housing for individuals with AD.

The following video will take you on a tour of the village. Although it has not been translated into english, it provides a nice visual of its set up and accomodations.

“France Builds First Alzheimer’s ‘Village’ in Pioneering Experiment.” BBC News, BBC, 5 June 2018,
“La Maladie.” Village Alzheimer,
Samuel, Henry. “France Starts Work on Revolutionary ‘Alzheimer’s Village’ Where Patients Roam Almost Free.” The Telegraph, Telegraph Media Group, 4 June 2018,

Physical Activity Helps Delay AD Progression

We have all been told how important it is for our health to lead an active lifestyle. Physical activity has many positive health benefits, but research is showing that it also has a protective effect on your brain!

According to a longitudinal study published in the July online edition of JAMA Neurology, physical activity and the management of other vascular risk factors – such as hypertension, diabetes, high cholesterol, atrial fibrillation and smoking – battle the progression of Alzheimer’s disease (AD).

Participants in this research were part of the Harvard Brain Study and were followed for up to 8 years. All of these individuals had positive amyloid PET scans and vascular risk at the beginning of the study. 

Physical activity was measured using pedometers that were worn around the waist, providing their mean steps per day. Participants also completed cognitive tests at baseline and throughout the study to monitor for decline. Amyloid levels were also monitored longitudinally for each participant.

Researchers found that modest regular physical activity (8,000-9,000 daily steps) was associated with slower brain volume loss over time and greater physical activity in those with high amyloid plaque burden protects against cognitive decline. 

The study also showed that the effect of physical activity on cognitive decline was independent of how well the subject’s vascular risk factors were being managed and controlled. These are two separate variables that have a profound influence on brain health that can be thoughtfully managed throughout life to promote brain health and longevity.

It is impossible to say exactly how much exercise is needed because every individual is different, but working to include modest regular activity into your daily routine will benefit you in the long run.

Not sure what to do for exercise? Keep it exciting! 

Rotate or have a good mix of resistance training, aerobic exercise, and mind-body exercises.

If you have not been engaging in any form of physical activity it’s not too late to begin! Just make sure to ease in to a routine and begin with gentle exercises to avoid injury. Over time you can increase the intensity of the activity or workout.

Here are some creative ways to get the body moving and get your steps in!

  • Find a walking buddy
  • Take a lunchtime walk
  • Park a little farther away at the store
  • Set an alarm to remind you when it’s time to walk or exercise
  • Look up walking exercise videos on YouTube
  • Take your dog on a walk
  • Take the stairs instead of elevators
  • Pace while watching your favorite TV shows, or take walk breaks during commercials
  • Dance!
  • Explore a new neighborhood/area with a friend or family member
  • Break it up, those small walks add up!
  • Walk in the mall 

What if I can’t walk?

There are still ways you can engage the body physically if you are unable to walk or have limited mobility. There are strength training and aerobic workouts that can be done in a chair. Great videos of these workouts can be found on YouTube that you can follow along and get your body moving!

Don’t forget that along with physical activity, you can also do other things to lower your risk of AD progression including stress reduction, proper nutrition, healthy sleep, social interaction, and maintaining stimulating hobbies/activities.

Gomes-Osman J. What kinds of exercise are good for brain health? [Internet]. Harvard Health Blog. 2018 [cited 2019Sep24]. Available from:
Physical Activity Moderates Amyloid-Beta Burden in… : Neurology Today [Internet]. LWW. [cited 2019Sep24]. Available from:
Harvard Health Publishing. A Guide to Cognitive Fitness [Internet]. Harvard Health. [cited 2019Sep24]. Available from:
6 Pillars of Brain Health – Physical Exercise [Internet]. Healthy Brains by Cleveland Clinic. [cited 2019Sep24]. Available from:

Intermittent Fasting, Could It Help Protect Your Brain While Aging?

Why do people get Alzheimer’s disease (AD)?

The cause of this disease is still widely unknown, but after many years of studying AD caloric intake, neuroscience professor Mark Mattson suggests that it may have to do with our modern eating habits. Mattson is particularly focused on the timing and frequency of our meals and how this affects our brains. 

Intermittent fasting, also known as caloric restriction, may not just be a tool used to achieve weight loss goals. When you adopt intermittent fasting into your lifestyle, you are cycling through short periods of eating and longer periods of fasting.

Historically, humans would naturally fast in between periods of hunting and gathering foods, as food was not as accessible as it is today.  Stocked kitchens and pantries allow us easier access to food at any hour of the day, and early breakfasts and late-night snacking have made it harder for humans to achieve our natural fasting state. This hinders the body’s ability to metabolically switch from using glycogen to ketones for fuel.

Glycogen is derived from the glucose in carbohydrates that we eat and is used as fuel for up to 12 hours after we eat. If we don’t use all our glycogen between meals it is turned to fat. Ketones are derived from our fat reserves and take over after the glycogen is all used up. Fasting shifts our energy production from glycogen to ketones.

Both glycogen and ketones fuel our neurons, but higher ketone production has been linked to improvements in thinking, learning, and memory. 

Fasting is quickly showing strong potential for the treatment of AD as it has been shown to slow cognitive decline and improve AD symptoms in mice. In several studies, researchers used genetically altered mice displaying AD symptoms. The mice that were fed on an intermittent fasting diet were better off than those that were allowed to eat whenever they wanted. The fasting mice showed better cognitive functioning and had less plaque buildup in their brains. They also lived longer than the mice that were not fasting.

Fasting can also lower oxidative stress. Oxidative stress occurs when we breakdown the food we eat to utilize the energy from the sun.  Unfortunately, the very process that keeps us alive, accessing the sun’s energy from our food via free radical formation, damages our cellular function as we age and contributes to the development of Alzheimer’s disease and the aging process — the more we eat the more we rust! Fasting upregulates free radical scavengers and anti-oxidants.

Diets that are high in simple sugars are associated with an increased risk for developing AD, the worst being refined sugar. Currently there are several clinical trials studying the link between nutrition and neurodegenerative diseases as there is still much to be learned about caloric restriction as a form of treatment or prevention. 

Managing caloric intake reduces body fat mass and provides other age-related benefits such as supporting healthy weight loss which, in a recent clinical trial, was associated with cognitive improvement in elderly individuals with Mild Cognitive Impairment (MCI).

Does this mean you should immediately start fasting?

Until more is known about the effectiveness of intermittent fasting in the prevention of AD, the best thing to do is to reconsider those late night snacks and limit your eating to about 12 hours a day, making sure to fast for the other 12 hours. If this 12/12 regime is not unpleasant for you, attempt a 16/8 fasting regime in which you skip breakfast, having only tea or coffee without sugar, and stop eating dinner at 8:00pm.  A regimen such as this can help protect your brain as you age and make other positive contributions to your overall health. One of the worst things you can do is eat a large dinner and then go right to sleep, so make sure to stop taking in calories about 3 hours before bedtime. 

The following video features professor Mark Mattson discussing theories and findings related to intermittent fasting and the benefits it can have when adopted into your lifestyle.

The Growing Science Behind a Fasting Treatment for Alzheimer’s [Internet]. The Crux. 2019. Available from:
Markesbery WR. The Role of Oxidative Stress in Alzheimer Disease [Internet]. Archives of Neurology. American Medical Association; 1999. Available from:


AFA’s New Online Memory Screen

The Alzheimer’s Foundation of America (AFA) have added a new tool to their website in the form of an Online Screening Test that can help determine whether or not a visit to your doctor may be beneficial to you. This test only takes a few minutes to complete.

To begin the test, a prompt on the screen will provide you with instructions on how to correctly complete the test. The test itself is simple, presenting you with a series of images. When an exact repeat image appears on the screen, the spacebar is pressed on the keyboard. It is important to respond quickly because your reaction time is taken into account. When the test is completed you will be shown your results. These results tell you your percent correct, your mean reaction time, and a short test analysis. The test analysis section provides a range of how you performed on the test in terms of above average, average, or below average for your age group. If your score is interpreted as below average, it may suggest that you retake the test after reviewing the instructions. If your score does not improve the next time you take the test, a clinical evaluation may be a good idea.

How is this screening test helpful?

Executive dysfunction and impaired working memory are two early indicators of Alzheimer’s disease (AD). Alzheimer’s disease can begin causing executive dysfunction before any signs of memory loss begin to emerge.

Assessments, such as the AFA’s Online Memory Screen, that are targeted towards working memory, attention, and executive functioning help with the early detection of AD symptoms. As we have discussed in past blog postings, it is crucial to begin monitoring and addressing AD symptoms at the earliest sign possible in the hope of preventing progression to more severe AD symptoms for as long as possible.

Working memory is the brain’s ability to hold information in our minds for a brief time and work with it. A good example of this is if you try to prepare a Thanksgiving meal. There are many components to keep track of all at the same time, and you will need to recall the steps of the recipe that you have already completed. This online screening test is similar because it is asking you to assess images and hold them in your working memory, while also continuing to look at more images and sort through them.

What is encoding?

Encoding is when you initially learn information and is the first step in creating a new memory. This new information is then maintained over time, stored throughout the brain, and is available to be retrieved as it’s needed. Encoding is selective, as we are exposed to many stimuli throughout any given day of our lives and it is impossible to remember all of it. As more symptoms of Alzheimer’s disease begin to appear, the hippocampus starts to shrink and the brain’s ability to encode new information and form new memories becomes compromised. The hippocampus is also important for the retrieval of old memories.

It is important to remember that screening tests are not meant to diagnose AD or other conditions, but are to help with earlier diagnosis so that preventative and protective measures can be taken as early as possible.

Here is the link to access the online memory screen: AFA Online Memory Screen

*If you have any questions regarding your score on the Online Memory Screen, the AFA has a staffed National Toll Free Helpline available for you to call at 866-232-8484. The line is open from 9AM-9PM ET Mon-Fri, and 9AM-1PM ET Sat-Sun.

Memory Encoding – Memory Processes – The Human Memory. [cited 2019Aug6]. Available from:
Executive Functioning – Where is it Controlled and How Does it Develop? / Remediation Techniques for Deficits and Dysfunction [Internet]. Rainbow Rehabilitation Centers. 2017 [cited 2019Aug6]. Available from:
Jahn H. Memory loss in Alzheimer’s disease [Internet]. Dialogues in clinical neuroscience. Les Laboratoires Servier; 2013 [cited 2019Aug6]. Available from:
Heerema E. How Executive Functioning Is Affected by Dementia [Internet]. Verywell Health. Verywell Health; 2019 [cited 2019Aug6]. Available from:
Kirova, Anna-Mariya, B. R, Sarita. Working Memory and Executive Function Decline across Normal Aging, Mild Cognitive Impairment, and Alzheimer’s Disease [Internet]. BioMed Research International. Hindawi; 2015 [cited 2019Aug6]. Available from:
Memory (Encoding, Storage, Retrieval) [Internet]. Noba. [cited 2019Aug6]. Available from:
Welcome to the Alzheimer’s Foundation of America’s Memory Screening Test [Internet]. AFA Online Memory Screening Test RSS. [cited 2019Aug6]. Available from:

Benefits of Turmeric (Curcumin)

Turmeric is a commonly used natural spice in South Asian cuisine such as curry. It is a common question whether or not turmeric and curcumin are the same thing. Turmeric is the plant itself, and curcumin is a compound found within turmeric.

Turmeric is used in traditional South Asian medicine to relieve wounds, gallstones, cramps, and Alzheimer’s disease (AD) symptoms. There is a growing amount of research being done regarding curcumin as an effective antioxidant and anti-inflammatory agent with the ability to improve cognitive functions in those with AD. Scientists report that Alzheimer’s disease for Indians aged 70-79 is four times lower than the rate in the United States. Several studies report turmeric(curcumin) to be equally as effective as donepezil(Aricept) in some cases. 

Top 10 documented uses of Turmeric and Curcumin

  • Memory Improvement
  • Heart Strengthener
  • Healthier Skin
  • Better Digestion
  • Less Dry Eye
  • Seasonal Allergy Relief
  • Artery Health
  • Diabetes
  • Better Liver Function
  • Arthritis Pain Relief

Reported benefits of turmeric include: anti-inflammatory properties, pain relief, improved liver function, reduced cancer risk, aids digestion, and immune health support.

How does Turmeric ( Curcumin) affect Alzheimer’s disease?

Both amyloid plaques and tau tangles are the basic pathologic markers of AD and initiate neuroinflammation causing more damage to thebrain because the immune system tries to clear these “foreign invaders”. These plaques and tangles accumulate, contributing to a decline in cognitive performance and memory loss. Research suggests that curcumin binds with the amyloid beta proteins, and due to its strong anti-inflammatory properties, prevents amyloid from resulting in further damage the brain.Curcumin decreases the level of oxidized proteins and isoprostanes in the brain while also suppressing Presenilin-1 activity (the BASE enzyme that make toxic AB-40/42), inhibiting further production of amyloid. Curcumin has also been found to have a high binding affinity for iron and copper; metals that can accelerate oxidative damage in the brain.

How much turmeric do I take?

The dosage of turmeric and curcumin extract vary depending on the form you are taking it in.

There are no official guidelines for the intake of turmeric, but the acceptable dietary intake is 1.4 mg per pound (3mg/kg) of body weight. This guideline was determined by The Joint FAO/WHO Expert Committee on Food Additives (JECFA).

If you are just taking curcumin extract, the dosage is unknown, but there are currently clinical trials being done to investigate a safe and effective dosage. 

Before deciding to add turmeric or curcumin extract into your daily routine, consult with your doctor. Be sure to consider the quality of the powder or supplement when deciding which one to purchase. Some powdered forms have additives or cheap fillers that may be hard to identify solely from the label. It is recommended to choose turmeric from a reputable agency, such as one that is USDA Certified Organic.

What if I don’t want to take the powdered form?

Turmeric can be added into your diet by getting creative in the kitchen and spicing up your recipes! For some inspiration check out some of these possible recipes from BBC Goodfood.

Are there side effects?

The most commonly reported side effect is stomach upset when taking turmeric. In some cases it also can cause a headache. A skin rash may occur when taking extremely high doses, although this is rare.

Adalier, Nur, and Heath Parker. “Vitamin E, Turmeric and Saffron in Treatment of Alzheimer’s Disease.” Antioxidants, vol. 5, no. 4, 2016, p. 40., doi:10.3390/antiox5040040.
Bhat, Abid, et al. “Benefits of Curcumin in Brain Disorders.” BioFactors (Oxford, England), 2019, doi:10.1002/biof.1533.
Tweed, Vera. “10 Benefits of Turmeric and Curcumin: The Popular Curry Spice and Its Active Ingredient (Curcumin) Offer a Wide Array of Uses for Health and Wellness.(Check OUT: GUIDE TO CUTTING-EDGE SUPPLEMENTS).” Better Nutrition, vol. 80, no. 5, 2018, p. 26.

Current Alzheimer’s Drugs and What They Do

With so many advertisements claiming that certain medications treat Alzheimer’s disease, how can we tell which one’s are legitimate?

There are 4 FDA approved medications for the treatment of Alzheimer’s disease (AD) in the United States. These drugs are not cures for the disease, but rather, help better manage the symptoms that effect memory and thinking.

There are two types of medications that are FDA approved to treat the cognitive symptoms brought on by Alzheimer’s, cholinesterase inhibitors and memantine.

The three commonly prescribed cholinesterase inhibitors are Donepezil (Aricept), Rivastigmine (Exelon), and Galantamine (Razadyne). These three medications are generally used during the mild to moderate stages of Alzheimer’s disease.

But what is a cholinesterase inhibitor?

Cholinesterase inhibitors work to prevent the breakdown of acetylcholine, which is a chemical in the brain that is part of the attention,  learning and memory circuits. Cholinesterase inhibitors have side effects mainly on the GI system. However, not everyone will get a response on these drugs; the effectiveness of these drugs varies from person to person. For people in later stages of AD, it may be harder to notice the assistance that these drugs can offer.

Memantine (Namenda) helps to regulate glutamate in the brain. Glutamate is a neurotransmitter in the brain that is responsible for sending signals between nerve cells. Memantine is typically used in the later, more severe stages of AD, but it can also be given to early stage patients to target anxiety and irritability.

New drugs are being tested to attempt to slow the progression of Alzheimer’s disease or even modify the disease process itself so that it does not have the opportunity to come to fruition as full blown Alzheimer’s disease. Common targets that experimental drugs are focusing on are Beta-amyloid, Beta-secretase, Tau protein, Inflammation, and the 5-HT2A receptor.

What about alternative treatments I’ve seen advertised?

There are many over-the-counter drugs and dietary supplements that claim to treat AD, delay AD, or enhance memory and thinking. However, these products have not been evaluated and approved by the Food and Drug Administration as safe or effective treatments for Alzheimer’s. In some cases, these products may negatively interact with prescribed medications already being taken in the course of treatment.

Always discuss any new herbal remedies, dietary supplements, or alternative treatments with a medical professional before adding any into your daily routine. If you see a new treatment available that interests you, make sure to do the research and bring information with you to discuss with your doctor.

The following video offers a visual explanation of cholinesterase inhibitors and memantine!

khanacademymedicine. Treatment of dementia and Alzheimer’s disease | Mental health | NCLEX-RN | Khan Academy [Internet]. YouTube. YouTube; 2015 [cited 2019Jul16]. Available from:
Medications for Memory [Internet]. Alzheimer’s Disease and Dementia. [cited 2019Jul16]. Available from:
Zhou Y, Danbolt NC. Glutamate as a neurotransmitter in the healthy brain [Internet]. Journal of neural transmission (Vienna, Austria : 1996). Springer Vienna; 2014 [cited 2019Jul16]. Available from:

Our Stories

Our Stories, by the Alzheimer’s Association, features the unique stories of 5 individuals with Alzheimer’s disease. These interactive stories help to notice changes in yourself or a loved one, and give tips on starting conversations about health concerns. It can be difficult to know what to do or say, but the stories of Cynthia, Mario, Julie, Theresa, and Tom are helpful guides in how to approach different situations.

It can be difficult to know what to say when you suspect someone important to you is experiencing memory problems, thinking problems, or behavior changes. Early detection of these problems offers significant benefits for an individual who is diagnosed with Alzheimer’s.  Benefits of early diagnosis include medical benefits, emotional and social benefits, more time to plan for the future, and cost savings. Further explanations of these benefits can be found here.

The biggest question is, How do you know when it’s time to have conversations like these? What if the concerns you have are part of normal aging?

Topics that can lead to a conversation about your concerns include:

  • challenges in planning
  • changes in mood
  • confusion with time and place
  • decreased judgment
  • difficulty completing tasks
  • memory loss
  • misplacing things
  • problems with words
  • trouble with visuals
  • social withdrawal

The Our Stories website also offers help by providing conversation starters with their 10 Steps To Approach Memory Concerns With A Loved One worksheet.

This 10 step guide is available to help you feel more confident and comfortable as you start to begin this discussion and take action. The steps navigate through three different categories:

  1. Assess The Situation
  2. Take Action Through Conversation
  3. Reach Out For Help

Each step is related to one of these three categories and suggests a course of action to be taken.

You can print out this guide and fill it out at your own pace and to meet your individual needs.

In some instances, you may be the one experiencing and noticing changes in your own memory or behavior. It can be hard to discuss concerns about your health with loved ones or trusted friends. There is also a version of the above guide that suggests what steps to take when you notice these changes in yourself, and how to begin conversations and seek support.

Find these amazing resources here at Our Stories!

Our Stories. [cited 2019Jul9]. Available from:
Why Get Checked? [Internet]. Alzheimer’s Disease and Dementia. [cited 2019Jul9]. Available from:

The Relationship Between Amyloid, Tau, and Cognition

A recent article published on ALZFORUM discussed research from the first longitudinal study that conducted repeated scans on older adults for both amyloid and tau over several years, and correlate those PET scan results with cognitive changes.

Scans were analyzed from 60 men and women that took part in the Harvard Aging Brain Study who were cognitively healthy and between the ages of 65 and 85 years of age. In addition to the scans, the participants completed cognitive testing each year to monitor cognitive changes. Participants were divided into groups of high and low amyloid as measured from the initial scan.

Over the years of the study, amyloid and tau levels rose in both of the groups and cognitive scores decreased. Those with the faster rate of tau accumulation had the fastest cognitive decline. On average, this entire process was sped up in the group with higher levels of amyloid in the brain initially.

Amyloid is deposited in the brain years before symptoms of Alzheimer’s disease begin to appear. This makes amyloid PET scans the most useful tool in detecting early pathology of the disease.

The study mentioned above shows that a reduction of tau may help to preserve cognition in those with high amyloid accumulation.  

In brains without the presence of amyloid, the tau tangles stay confined to the medial temporal lobe as a part of normal aging. In brains where amyloid is present, the tau tangles invade the surrounding areas of the brain.

Studies support the theory that tau spreads through interconnected neurons, and that the spreading of tau depends of the presence of amyloid, as well as, the functional and structural connections between regions of the brain.

In addition to amyloid PET scans, tau PET scans are useful to track disease progression in clinical trials research. Currently, cognitive tests are helpful in tracking the progression, but take a long time to show any significant responses to clinical trials drugs.

Because amyloid may boost the accumulation of tau, people who accumulated amyloid at a fast rate throughout the study, experienced the most rapid increase of tau, and the largest cognitive decline.

Amyloid alone (without any presence of tau) has a weak affect on cognition, but as amyloid levels rise, it triggers a burst of tau production with ensuing cognition loss.

These findings help put the pieces in temportal order: amyloid, tau, and then cognitive decline. Tau PET biomarkers may get us closer to finding an effective disease modifying drug to combat Alzheimer’s disease. Larger studies will be needed to further evaluate this data and to fully understand the progression of this disease.

Serial PET Nails It: Preclinical AD Means Amyloid, Tau, then Cognitive Decline [Internet]. ALZFORUM. [cited 2019Jun19]. Available from: